Ge Xin, Shen Zichu, Yin Yuxin
Peking University First Hospital, Beijing, 100034, China.
Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking-Tsinghua Center of Life Sciences, Peking University Health Science Center, Beijing, 100191, China.
Cancer Cell Int. 2024 Nov 9;24(1):369. doi: 10.1186/s12935-024-03549-1.
Long non-coding RNAs (lncRNAs) are emerging as crucial regulators of gene expression through diverse mechanisms, including regulation of protein localization, sequestration of miRNAs, recruitment of chromatin modifiers, and modulation of signaling pathways. Accumulating evidence highlights their pivotal roles in tumor initiation, progression, and the development of therapeutic resistance. In this review, we comprehensively summarized the existing literature to identify lncRNAs associated with treatment responses in non-small cell lung cancer (NSCLC). Specifically, we categorized these lncRNAs based on their mechanisms of action in mediating resistance to chemotherapy, targeted therapy, and radiotherapy. Our analysis revealed that aberrant expression of various lncRNAs contributes to the development, metastasis, and therapeutic resistance in NSCLC, ultimately leading to poor clinical outcomes. By elucidating the intricate mechanisms through which lncRNAs modulate therapeutic responses, this review aims to provide mechanistic insights into the heterogeneous treatment outcomes observed in NSCLC patients and unveil potential therapeutic targets for overcoming drug resistance.
长链非编码RNA（lncRNAs）正通过多种机制成为基因表达的关键调节因子，这些机制包括蛋白质定位的调节、微小RNA（miRNAs）的隔离、染色质修饰因子的招募以及信号通路的调控。越来越多的证据凸显了它们在肿瘤起始、进展以及治疗耐药性发展中的关键作用。在本综述中，我们全面总结了现有文献，以确定与非小细胞肺癌（NSCLC）治疗反应相关的lncRNAs。具体而言，我们根据这些lncRNAs在介导对化疗、靶向治疗和放疗耐药性中的作用机制对其进行了分类。我们的分析表明，各种lncRNAs的异常表达促成了NSCLC的发生、转移和治疗耐药性，最终导致不良的临床结局。通过阐明lncRNAs调节治疗反应的复杂机制，本综述旨在为NSCLC患者中观察到的异质性治疗结果提供机制性见解，并揭示克服耐药性的潜在治疗靶点。
